News
Modification of Criteria for Diagnosing Irritable Bowel Syndrome in Clinical Practice
The Rome criteria for diagnosing disorders of gut-brain interaction (DGBI) have recently been modified due to discrepancies with their use in clinical practice. The Rome Foundation board has created modified Rome IV diagnostic criteria. When caring for patients with DGBI, including irritable bowel syndrome (IBS), it will be possible to diagnose even with shorter duration and lower frequency of symptoms.
Prediabetes as a Risk Factor for Overall Mortality and Development of CVD
Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes.…
XR vs. IR Form of Metformin − It’s Not Just About Gastrointestinal Tolerability
It is well known that the XR form of metformin shows better gastrointestinal tolerability. However,…
What affects the elimination of bisoprolol in diabetics and patients with acute coronary syndrome?
Beta-blockers are widely used to reduce cardiovascular (CV) risk in a number of diseases. However,…
What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran
Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The…
Interchangeability of Diosmin and Micronized Purified Flavonoid Fraction
Among the medicinal products reimbursed for chronic venous disease, those containing micronized…
Ceftaroline as a Treatment Option for MRSA-Induced Sepsis?
A recently published study by a team of authors from several American institutions focused on…
Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk
Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum…
Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism
The relationship between the level of antithyroid antibodies and the required dose of levothyroxine…
Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and…